Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLESTAR: Olaparib and Pembrolizumab in Gastric/GEJ Cancer
NCT05268510Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started Sep 2022; status: completed.
02
Drugs
olaparib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05268510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268510.